Ticker	Current Price	Change	Graph
IBB	113.64	0.21 (0.18%)
XBI	90.93	0.31 (0.34%)

New Capital, Venture Capital

Flagship ties up a monster $824M fund to back a new wave of biotech startups seeded in their lab

FDA, New Products

UPDATED: FDA approves trailblazing postpartum depression therapy, in crucial milestone for women's health

Pricing

UPDATED: With eye on revenue stabilization, Gilead takes 4.9% hike on a basket of drugs

Latest

NASH drug in hand, Merck forges ahead with 2-year extension of NGM Bio collaboration deal →

EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet →

Pfizer lines up a potential $687M rare disease buyout to expand its stake in the hot gene therapy field →

GlaxoSmithKline sets its sights on a quick leap into the big PD-1/L1 game — will anyone notice? →

Following Syntimmune buyout, Alexion antes up $25M to double down on anti-FcRn pathway →

Pfizer, Merck KGaA throw in the towel on another Bavencio PhIII as once bright hopes shrivel fast →

Seeking a place among giants in the oncolytic virus field, little Cold Genesys bags $22M Series C →

Skin regeneration company PolarityTE reveals SEC investigation, probing into its lead product, former CFO and current investors →

Bristol-Myers and Starboard Value spar over $74B Celgene buyout as shareholder vote looms →

Roche, AbbVie forced to slam brakes on myeloma studies of star drug Venclexta after researchers flag higher risk of death →

Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival →

Roche stacks up Tecentriq nods, following up breast cancer approval with small cell lung cancer →

Top News

Is a new CEO in the cards at Sanofi as succession planning heats up for top team?

John Carroll

Partnering talks led to Biogen’s $800M Nightstar buyout as players clustered around the hot deal table for gene therapies

John Carroll

Amarin posts another round of promising cardio outcomes data for Vascepa. Cue more M&A chatter and argument

John Carroll

Biohaven is betting hundreds of millions it can hustle ahead of rivals in a blockbuster race. A quick M&A deal could pay off backers big time

John Carroll

Oncology dominates a 'Cambrian explosion' in China's drug pipeline as McKinsey guru bets on a burst of innovation

Amber Tong

More news

Protocols

Quick hits from around the biopharma web

Mar 20

To tackle soaring prescription drug costs, Canada creates new agency to negotiate prices; DMC clears phIII testing of Cytokinetics' Amgen-partnered heart drug

Mar 19

Affimed lands milestone from Roche; Puma touts new PHII data on cervical cancer

Mar 18

Aimmune wins 12-month review and adcom for peanut allergy drug; PhaseBio flies on early data for Brilinta reversal agent

Mar 15

Genfit readies its $120M IPO; Karyopharm shares boosted after an FDA delay for selinexor

More Protocols

Peer Review

Weekly biopharma careers news report

Mar 15

AstraZeneca vet Jennifer Butler takes charge of Innate Pharma's US biz; C4 raids NIBR

Mar 8

From Agios to Deciphera, Steve Hoerter plots another oncology launch; Roche exec Christiane Hamachar moves to India as CEO of Biocon Biologics

Mar 1

ReViral taps Seth Hetherington to guide upcoming PhIIa; Incyte, Aquinox execs move to AI shop Notable Labs

Feb 22

Pfizer spinout woos Otsuka vet Raymond Sanchez to lead CNS pipeline work; Joe Anderson returns to Arix helm

More peer review

Premium

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals

The $100M biotech club: Who's in, and what’s it take to join the top-performing group of biopharmas?

The high rollers: The top 20 blockbuster biopharma deals of the past decade

Top 20 biotech deals: 2019 dealmaking gets off to a roaring start, building on a record amount for '18

AstraZeneca CEO Soriot is overseeing a top exec team overhaul in move to integrate MedImmune in a sweeping restructuring

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?

Bioregnum

The view from John Carroll

Mar 7

How do you replace a rock star like Scott Gottlieb at the FDA? Maybe you can't

Jan 29

As Pfizer kills failed PhIII programs for Bavencio, where do they go from here in R&D?

Jan 25

The antibiotics R&D effort is broken. Here's one market solution that might fix it

Jan 17

Short seller Citron draws fresh blood going after another biotech scalp — but can it still cut that deep?

More opinion

Marco

Top biopharma links on Twitter - last updated ago

Most Viral

FDA approves first treatment for post-partum depression

FDA a day

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics

BusinessWire a day

Catalyst says pricey drug doing 'better than expected' despite anger- STAT

STAT a day

Canada to create national drug agency to cut cost of medicines

Reuters David Ljunggren a day

Health Insurance Coverage and Health — What the Recent Evidence Tells Us

NEJM a day

Xconomy: FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take

Xconomy Ben Fidler a day

Xconomy: Pfizer Bolsters Gene Therapy Position with $51M Vivet Deal

Xconomy Ben Fidler a day

F.D.A. Approves First Drug for Postpartum Depression

New York Times Pam Belluck a day

Seven future blockbuster drugs to look out for in 2019 - Pharmaphorum

Pharmaphorum Phil Taylor a day

China needs 30 times its outsourcing capacity to meet drugs demand

South China Morning Post a day

Latest

Evaluate.com

ACC 2019 - Low risk of patients being denied transcatheter aortic valves

Yahoo

Italian Politician Who Opposed Mandatory Chickenpox Vaccine Sickened With Chickenpox

Evaluate.com

Sage's depression therapy arrives with big spread in sales forecasts

FiercePharma

See ya, Goodfella: #FierceMadness voters bounce Liotta, Tremfya and more in first-round play

FiercePharma

Pfizer, Merck KGaA scrap yet another Bavencio ovarian cancer trial

Europa

Draft agenda for the 103rd meeting of the Management Board

Pharmaphorum

Seven future blockbuster drugs to look out for in 2019 - Pharmaphorum

Mrknewsroom

Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022

Crunchbase News

Corporate Biotech Venture Funding Rises Again

Boston Business Journal

Venture capital firm Flagship Pioneering raises $824M for new life science investments - Boston Business Journal

Hot This Week

1

STAT

Amarin's Vascepa prevents second and third heart attacks in analysis

2

Kaiser Health News

Death By A Thousand Clicks

3

STAT

Next for Apple Watch: a clinical trial with J&J to track heart health - STAT

4

ENDPOINTS NEWS

Vivek Ramaswamy's Urovant claims a big win in PhIII - but questions linger about the cheap generic comparator

5

FDA

FDA approves first treatment for post-partum depression

6

BusinessWire

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics

7

Evaluate.com

Celyad spells out its off-the-shelf ambitions

8

STAT

Tiny PhaseBio gets the NEJM spotlight. Can its shares rebound? - STAT

9

Evaluate.com

ACC 2019 round-up - Esperion and Amarin prepare to go it alone

10

WSJ

Flagship ties up a monster $824M fund to back a new wave of biotech startups seeded in their lab

UPDATED: FDA approves trailblazing postpartum depression therapy, in crucial milestone for women's health

UPDATED: With eye on revenue stabilization, Gilead takes 4.9% hike on a basket of drugs

Latest

NASH drug in hand, Merck forges ahead with 2-year extension of NGM Bio collaboration deal →

EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet →

Pfizer lines up a potential $687M rare disease buyout to expand its stake in the hot gene therapy field →

GlaxoSmithKline sets its sights on a quick leap into the big PD-1/L1 game — will anyone notice? →

Following Syntimmune buyout, Alexion antes up $25M to double down on anti-FcRn pathway →

Pfizer, Merck KGaA throw in the towel on another Bavencio PhIII as once bright hopes shrivel fast →

Seeking a place among giants in the oncolytic virus field, little Cold Genesys bags $22M Series C →

Skin regeneration company PolarityTE reveals SEC investigation, probing into its lead product, former CFO and current investors →

Bristol-Myers and Starboard Value spar over $74B Celgene buyout as shareholder vote looms →

Roche, AbbVie forced to slam brakes on myeloma studies of star drug Venclexta after researchers flag higher risk of death →

Vivek Ramaswamy’s Urovant claims a big win in PhIII — but questions linger about a cheap generic and their branded rival →

Roche stacks up Tecentriq nods, following up breast cancer approval with small cell lung cancer →

Sponsored

Top News

Protocols

Peer Review

Premium

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel O’Day’s first M&A moves?

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

By the numbers: Top M&A deals, VC investments and pacts point to a growing hunger for gene therapy deals

The $100M biotech club: Who's in, and what’s it take to join the top-performing group of biopharmas?

The high rollers: The top 20 blockbuster biopharma deals of the past decade

Top 20 biotech deals: 2019 dealmaking gets off to a roaring start, building on a record amount for '18

AstraZeneca CEO Soriot is overseeing a top exec team overhaul in move to integrate MedImmune in a sweeping restructuring

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?

Bioregnum

Most Viral

Latest

Hot This Week

Contact Endpoints News

Sign in to Endpoints News

Request a magic link

Set a new password